C4 Therapeutics (NASDAQ: CCCC) CFO gets 240,000 RSU award, tax withholding

Rhea-AI Filing Summary

C4 Therapeutics, Inc. reported insider equity activity by Chief Financial Officer Kendra Adams. She received a grant of 240,000 restricted stock units (RSUs), which vest in stages through February 13, 2029, based on time and performance conditions.

Adams also acquired 30,950 and 3,750 shares of common stock through vesting and exercise of previously granted RSUs, and 15,381 and 1,863 shares were withheld by the company at $1.89 per share to cover tax obligations. After these transactions, she directly holds 385,098 shares of common stock.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Adams Kendra

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Common Stock	30,950	$0.00	--
Tax Withholding	Common Stock	15,381	$1.89	$29K
Grant/Award	Common Stock	240,000	$0.00	--
Exercise	Common Stock	3,750	$0.00	--
Tax Withholding	Common Stock	1,863	$1.89	$4K

Holdings After Transaction: Common Stock — 400,479 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adams Kendra

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A		240,000(1)	A	$0	402,342	D
Common Stock	02/13/2026		M(2)	V	3,750	A	$0	402,342	D
Common Stock	02/13/2026		F(3)		1,863	D	$1.89	400,479	D
Common Stock	02/14/2026		M(2)	V	30,950	A	$0	400,479	D
Common Stock	02/14/2026		F(3)		15,381	D	$1.89	385,098	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.

2. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.

3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did C4 Therapeutics (CCCC) disclose in this Form 4 for its CFO?

C4 Therapeutics reported that CFO Kendra Adams received a 240,000 RSU grant and had additional RSUs vest and settle into common stock, with some shares withheld to cover taxes. These transactions update her direct ownership position in the company’s stock.

How many RSUs were granted to the C4 Therapeutics (CCCC) CFO?

Kendra Adams received a grant of 240,000 restricted stock units. Half vest in three equal annual installments starting February 13, 2027, and the remaining 120,000 vest in full on February 13, 2029, subject to specified performance milestones being achieved.

Were any of the C4 Therapeutics (CCCC) CFO’s Form 4 transactions open-market sales?

No, the Form 4 shows no open-market sales. Shares labeled with transaction code “F” were withheld by C4 Therapeutics at $1.89 per share solely to satisfy tax obligations related to RSU vesting, which the filing states does not represent a sale by the CFO.

How many C4 Therapeutics (CCCC) shares does the CFO own after these transactions?

Following the reported RSU grant, vesting, exercises, and tax withholding, CFO Kendra Adams directly owns 385,098 shares of C4 Therapeutics common stock. This figure reflects her updated ownership after all transactions listed in the Form 4 were completed.

What is the vesting schedule for the new C4 Therapeutics (CCCC) RSU grant?

The 240,000 RSUs vest in two parts: 120,000 vest in three equal annual installments starting February 13, 2027, and the remaining 120,000 vest in full on February 13, 2029, with potential acceleration if certain performance milestones are met.